Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
Abstract Background Infection breakthrough after COVID-19 vaccination is a point of conflict in current literature not only because of the estimation of the potential hazards and symptoms severity but also due to establishing a vaccination policy and measuring the extent of immunity after vaccinatio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-04-01
|
| Series: | The Egyptian Journal of Bronchology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43168-023-00196-4 |
| _version_ | 1797841133348323328 |
|---|---|
| author | Aliae A. R. Mohamed Hussein Maiada K. Hashem Mohammed G. Azizeldine Ahmad M. Shaddad |
| author_facet | Aliae A. R. Mohamed Hussein Maiada K. Hashem Mohammed G. Azizeldine Ahmad M. Shaddad |
| author_sort | Aliae A. R. Mohamed Hussein |
| collection | DOAJ |
| description | Abstract Background Infection breakthrough after COVID-19 vaccination is a point of conflict in current literature not only because of the estimation of the potential hazards and symptoms severity but also due to establishing a vaccination policy and measuring the extent of immunity after vaccination in addition to the waning of the humoral immunity over time. To our knowledge, this is the first study to stratify the risk of post-COVID-19 vaccination breakthroughs in Upper Egypt. Methods In this cross-sectional observational study, we enrolled 369 vaccinated patients registered in our facility either admitted or in out-patient clinic. Patients were interviewed and any proven history of COVID-19 infection after vaccination was recorded. Results In the current study, 18.97% (70 patients) of the 369 subjects enrolled in the study had COVID-19breakthrough infection. Students were the high-risk group representing 18.6% of the study subjects. Hypertension, diabetes, and cardiac disease were the most comorbidities associated with a prevalence of 15.7%, 8.6%, and 4.3% respectively. Prior to COVID-19, confirmed infection was present in 42.9% of the study group. Fever, headache, myalgia, and cough were among the most common symptoms of the post-COVID vaccination breakthrough with a prevalence of 90%, 75.7%, 84.3%, and 74.3% respectively. Conclusion Breakthrough infection after COVID-19 vaccination is not uncommon. Most cases are mild and don’t require hospitalization. All types of vaccines tested in the current study offer adequate immunity and guard against severe COVID-19 infection. We encourage the current global policy of full vaccination. Trial registration ClinicalTrials.gov. NCT05033834. Registered September 5, 2021. COVID-19 Infection in After Vaccination-Full Text View-ClinicalTrials.gov. |
| first_indexed | 2024-04-09T16:26:06Z |
| format | Article |
| id | doaj.art-3755d8379afc4f6db935bd37dc7a1dd6 |
| institution | Directory Open Access Journal |
| issn | 2314-8551 |
| language | English |
| last_indexed | 2024-04-09T16:26:06Z |
| publishDate | 2023-04-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Bronchology |
| spelling | doaj.art-3755d8379afc4f6db935bd37dc7a1dd62023-04-23T11:11:18ZengSpringerOpenThe Egyptian Journal of Bronchology2314-85512023-04-011711810.1186/s43168-023-00196-4Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper EgyptAliae A. R. Mohamed Hussein0Maiada K. Hashem1Mohammed G. Azizeldine2Ahmad M. Shaddad3Chest Department, Assiut University Hospital, Assiut Faculty of Medicine, Assiut UniversityChest Department, Assiut University Hospital, Assiut Faculty of Medicine, Assiut UniversityChest Department, Assiut University Hospital, Assiut Faculty of Medicine, Assiut UniversityChest Department, Assiut University Hospital, Assiut Faculty of Medicine, Assiut UniversityAbstract Background Infection breakthrough after COVID-19 vaccination is a point of conflict in current literature not only because of the estimation of the potential hazards and symptoms severity but also due to establishing a vaccination policy and measuring the extent of immunity after vaccination in addition to the waning of the humoral immunity over time. To our knowledge, this is the first study to stratify the risk of post-COVID-19 vaccination breakthroughs in Upper Egypt. Methods In this cross-sectional observational study, we enrolled 369 vaccinated patients registered in our facility either admitted or in out-patient clinic. Patients were interviewed and any proven history of COVID-19 infection after vaccination was recorded. Results In the current study, 18.97% (70 patients) of the 369 subjects enrolled in the study had COVID-19breakthrough infection. Students were the high-risk group representing 18.6% of the study subjects. Hypertension, diabetes, and cardiac disease were the most comorbidities associated with a prevalence of 15.7%, 8.6%, and 4.3% respectively. Prior to COVID-19, confirmed infection was present in 42.9% of the study group. Fever, headache, myalgia, and cough were among the most common symptoms of the post-COVID vaccination breakthrough with a prevalence of 90%, 75.7%, 84.3%, and 74.3% respectively. Conclusion Breakthrough infection after COVID-19 vaccination is not uncommon. Most cases are mild and don’t require hospitalization. All types of vaccines tested in the current study offer adequate immunity and guard against severe COVID-19 infection. We encourage the current global policy of full vaccination. Trial registration ClinicalTrials.gov. NCT05033834. Registered September 5, 2021. COVID-19 Infection in After Vaccination-Full Text View-ClinicalTrials.gov.https://doi.org/10.1186/s43168-023-00196-4COVID-19BreakthroughCOVID-19 vaccinationSARS-COV-2 |
| spellingShingle | Aliae A. R. Mohamed Hussein Maiada K. Hashem Mohammed G. Azizeldine Ahmad M. Shaddad Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt The Egyptian Journal of Bronchology COVID-19 Breakthrough COVID-19 vaccination SARS-COV-2 |
| title | Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt |
| title_full | Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt |
| title_fullStr | Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt |
| title_full_unstemmed | Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt |
| title_short | Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt |
| title_sort | prevalence and characteristics of covid 19 vaccine breakthrough infection in upper egypt |
| topic | COVID-19 Breakthrough COVID-19 vaccination SARS-COV-2 |
| url | https://doi.org/10.1186/s43168-023-00196-4 |
| work_keys_str_mv | AT aliaearmohamedhussein prevalenceandcharacteristicsofcovid19vaccinebreakthroughinfectioninupperegypt AT maiadakhashem prevalenceandcharacteristicsofcovid19vaccinebreakthroughinfectioninupperegypt AT mohammedgazizeldine prevalenceandcharacteristicsofcovid19vaccinebreakthroughinfectioninupperegypt AT ahmadmshaddad prevalenceandcharacteristicsofcovid19vaccinebreakthroughinfectioninupperegypt |